Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest C1 platform technology Stories

2012-05-01 02:23:48

JUPITER, Fla., May 1, 2012 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic")(OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries, announced today that Abengoa Bioenergy New Technologies, Inc. ("Abengoa") has agreed to pay Dyadic $5.5 million for an expansion of its rights under the non-exclusive license agreement the...

2012-02-29 08:15:00

JUPITER, Fla., Feb. 29, 2012 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that it has entered into a research, development and license agreement with a leading global provider of nutritional ingredient solutions to use Dyadic's patented and proprietary C1...

2010-06-21 08:15:00

JUPITER, Fla., June 21 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI), a global biotechnology company whose cutting-edge C1 platform technology addresses the needs of the multi-billion dollar biofuels market by producing enzymes at industrial scale which efficiently convert biomass into ethanol and other forms of alternative energy, announced today that it has engaged the influential consulting firm, The Abraham Group, to provide strategic advice and transactional...